D. Sahali, V. Audard, P. Rémy, and P. Lang, Syndromes néphrotiques idiopathiques : physiopathologie et prise en charge thérapeutique spécifique chez l?adulte, Néphrologie & Thérapeutique, vol.8, issue.3, pp.180-192, 2012.

D. Sahali, K. Sendeyo, M. Mangier, V. Audard, S. Y. Zhang et al., Immunopathogenesis of idiopathic nephrotic syndrome with relapse, Seminars in Immunopathology, vol.36, issue.4, pp.421-429, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01059437

M. A. Saleem, Molecular stratification of idiopathic nephrotic syndrome, Nature Reviews Nephrology, vol.15, issue.12, pp.750-765, 2019.

S. Y. Zhang, V. Audard, Q. Fan, A. Pawlak, P. Lang et al., Immunopathogenesis of Idiopathic Nephrotic Syndrome, Contributions to Nephrology, vol.169, pp.94-106, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00596992

A. Boumediene, P. Vachin, K. Sendeyo, J. Oniszczuk, S. Zhang et al., NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome, Journal of Autoimmunity, vol.88, pp.91-102, 2018.

V. Audard, S. Zhang, C. Copie-bergman, C. Rucker-martin, V. Ory et al., Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes, Blood, vol.115, issue.18, pp.3756-3762, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00485558

T. Li, Y. Shi, W. Sun, H. Wang, Q. Wang et al., Increased PD-1+CD154+ Tfh cells are possibly the most important functional subset of PD-1+ T follicular helper cells in adult patients with minimal change disease, Molecular Immunology, vol.94, pp.98-106, 2018.

V. Audard, P. Lang, and D. Sahali, Pathogénie du syndrome néphrotique à lesions glomérulaires minimes, médecine/sciences, vol.24, issue.10, pp.853-858, 2008.

C. A. Peh, Commentary on the KDIGO Clinical Practice Guideline for Glomerulonephritis, Nephrology, vol.18, issue.7, pp.483-484, 2013.

M. E. Reff, K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, vol.83, issue.2, pp.435-445, 1994.

E. Kimby, Tolerability and safety of rituximab (MabThera®), Cancer Treatment Reviews, vol.31, issue.6, pp.456-473, 2005.

M. D. Cohen and E. Keystone, Rituximab for Rheumatoid Arthritis, Rheumatology and Therapy, vol.2, issue.2, pp.99-111, 2015.

D. Dierickx, G. Verhoef, A. Van-hoof, P. Mineur, A. Roest et al., Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study, Journal of Internal Medicine, vol.266, issue.5, pp.484-491, 2009.

C. J. Kushner, S. Wang, N. Tovanabutra, D. E. Tsai, V. P. Werth et al., Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus, JAMA Dermatology, vol.155, issue.12, p.1404, 2019.

D. G. Noone, K. Iijima, and R. Parekh, Idiopathic nephrotic syndrome in children, The Lancet, vol.392, issue.10141, pp.61-74, 2018.

K. Lijima, M. Sako, and K. Nozu, Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind,randomised, placebo-controlled trial, Lancet, 2014.

P. Ravani, A. Magnasco, A. Edefonti, L. Murer, R. Rossi et al., Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome: A Randomized Controlled Trial, Clinical Journal of the American Society of Nephrology, vol.6, issue.6, pp.1308-1315, 2011.

P. Ravani, R. Rossi, A. Bonanni, R. R. Quinn, F. Sica et al., Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial, Journal of the American Society of Nephrology, vol.26, issue.9, pp.2259-2266, 2015.

K. Kamei, M. Okada, M. Sato, T. Fujimaru, M. Ogura et al., Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome, Pediatric Nephrology, vol.29, issue.7, pp.1181-1187, 2014.

H. Munyentwali, K. Bouachi, V. Audard, P. Remy, P. Lang et al., Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease, Kidney International, vol.83, issue.3, pp.511-516, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00919110

A. Bruchfeld, S. Benedek, M. Hilderman, C. Medin, S. Snaedal-jonsdottir et al., Rituximab for minimal change disease in adults: long-term follow-up, Nephrology Dialysis Transplantation, vol.29, issue.4, pp.851-856, 2013.

L. C. Brown, M. A. Jobson, F. Payan-schober, E. H. Chang, R. J. Falk et al., The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy, American Journal of Nephrology, vol.45, issue.4, pp.365-372, 2017.

H. Sugiura, T. Takei, M. Itabashi, M. Tsukada, T. Moriyama et al., Effect of Single-Dose Rituximab on Primary Glomerular Diseases, Nephron Clinical Practice, vol.117, issue.2, pp.c98-c105, 2011.

Y. Iwabuchi, T. Takei, T. Moriyama, M. Itabashi, and K. Nitta, Long-Term Prognosis of Adult Patients with Steroid-Dependent Minimal Change Nephrotic Syndrome Following Rituximab Treatment, Medicine, vol.93, issue.29, p.e300, 2014.

E. Papakrivopoulou, A. M. Shendi, A. D. Salama, M. Khosravi, J. O. Connolly et al., Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease, Nephrology, vol.21, issue.10, pp.893-900, 2016.

F. B. Cortazar, J. Rosenthal, K. Laliberte, and J. L. Niles, Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome, Clinical Kidney Journal, vol.12, issue.2, pp.224-231, 2018.

A. Salar, I. Avivi, B. Bittner, R. Bouabdallah, M. Brewster et al., Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study, Journal of Clinical Oncology, vol.32, issue.17, pp.1782-1791, 2014.

A. Davies, F. Merli, B. Mihaljevic, N. Siritanaratkul, P. Solal-céligny et al., Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study, The Lancet Oncology, vol.15, issue.3, pp.343-352, 2014.

M. Rummel, T. M. Kim, F. Aversa, W. Brugger, E. Capochiani et al., Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab), Annals of Oncology, vol.28, issue.4, pp.836-842, 2017.

S. Network, R. T. Harbour, and L. Forsyth, SIGN 50: A Guideline Developer's Handbook. Ediburgh, Scotland: Scottish Intercollegiate Guidelines Network, 2008.

D. J. Pierson, How to read a case report (or teaching case of the month), Respir Care, vol.54, issue.10, pp.1372-1378, 2009.

A. S. Levey, L. A. Stevens, C. H. Schmid, Y. (. Zhang, A. F. Castro et al., A New Equation to Estimate Glomerular Filtration Rate, Annals of Internal Medicine, vol.150, issue.9, p.604, 2009.

A. S. Levey, J. Coresh, T. Greene, J. Marsh, L. A. Stevens et al., Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values, Clinical Chemistry, vol.53, issue.4, pp.766-772, 2007.

A. Fornoni, J. Sageshima, C. Wei, S. Merscher-gomez, R. Aguillon-prada et al., Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis, Science Translational Medicine, vol.3, issue.85, pp.85ra46-85ra46, 2011.

C. Bezombes, S. Grazide, and C. Garret, Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains, Blood, vol.104, issue.4, pp.1166-1173, 2004.
URL : https://hal.archives-ouvertes.fr/hal-02349082

, Protocole national de diagnostic et de soins (PNDS). Syndrome néphrotique idiopathique de l?enfant, Journal de Pédiatrie et de Puériculture, vol.30, issue.1, pp.32-42, 2017.

B. H. Rovin, D. J. Caster, and D. C. Cattran, Management and treatment of glomerular diseases, conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, vol.95, pp.281-295, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02380917

A. Gulati, A. Sinha, S. C. Jordan, P. Hari, A. K. Dinda et al., Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome: Multicentric Report, Clinical Journal of the American Society of Nephrology, vol.5, issue.12, pp.2207-2212, 2010.

A. El-husseini, F. El-basuony, I. Mahmoud, H. Sheashaa, A. Sabry et al., Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience, Nephrology Dialysis Transplantation, vol.20, issue.11, pp.2433-2438, 2005.

H. A. Kyrieleis, M. M. Löwik, I. Pronk, H. R. Cruysberg, J. A. Kremer et al., Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children, Clinical Journal of the American Society of Nephrology, vol.4, issue.10, pp.1593-1600, 2009.

G. Fernandez-fresnedo, A. Segarra, E. González, S. Alexandru, R. Delgado et al., Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis, Clinical Journal of the American Society of Nephrology, vol.4, issue.8, pp.1317-1323, 2009.

D. Roccatello, S. Sciascia, D. Rossi, M. Alpa, C. Naretto et al., High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study, American Journal of Nephrology, vol.46, issue.2, pp.108-113, 2017.

A. Sinha and A. Bagga, Rituximab therapy in nephrotic syndrome: implications for patients' management, Nature Reviews Nephrology, vol.9, issue.3, pp.154-169, 2013.

D. M. Roberts, R. B. Jones, R. M. Smith, F. Alberici, D. S. Kumaratne et al., Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease, Journal of Autoimmunity, vol.57, pp.60-65, 2015.

L. Mozessohn, K. K. Chan, J. J. Feld, and L. K. Hicks, Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis, Journal of Viral Hepatitis, vol.22, issue.10, pp.842-849, 2015.

I. Martin-garrido, E. M. Carmona, U. Specks, and A. H. Limper, Pneumocystis Pneumonia in Patients Treated With Rituximab, Chest, vol.144, issue.1, pp.258-265, 2013.

M. I. Domínguez-mozo, E. Toledano-martínez, L. Rodríguez-rodríguez, M. García-montojo, R. Alvarez-lafuente et al., JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab, Scandinavian Journal of Rheumatology, vol.45, issue.6, pp.507-511, 2016.

I. R. Rao, S. T. Pinnamaneni, M. Ranjana, N. Ritambhra, K. Vivek et al., Rituximab is effective as first line therapy in the management of steroid sensitive, but dependent/relapsing adult Nephrotic syndrome, Nephrology, vol.22, issue.9, pp.731-732, 2017.

E. Hoxha, R. A. Stahl, and S. Harendza, Rituximab in adult patients with immunosuppressive-dependent minimal change disease, Clinical Nephrology, vol.76, issue.08, pp.151-158, 2011.

T. Takei, M. Itabashi, T. Moriyama, C. Kojima, S. Shiohira et al., Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults, Nephrology Dialysis Transplantation, vol.28, issue.5, pp.1225-1232, 2012.

T. Kisner, V. Burst, S. Teschner, T. Benzing, and C. E. Kurschat, Rituximab Treatment for Adults with Refractory Nephrotic Syndrome: A Single-Center Experience and Review of the Literature, Nephron Clinical Practice, vol.120, issue.2, pp.c79-c85, 2012.

Y. Miyabe, T. Takei, Y. Iwabuchi, T. Moriyama, and K. Nitta, Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome, Clinical and Experimental Nephrology, vol.20, issue.1, pp.103-110, 2015.

H. Ren, L. Lin, P. Shen, X. Li, J. Xie et al., Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis, Oncotarget, vol.8, issue.55, pp.93438-93443, 2017.

R. Ramachandran, J. Bharati, I. Rao, A. W. Kashif, R. Nada et al., Persistent CD?19 depletion by rituximab is cost?effective in maintaining remission in calcineurin?inhibitor dependent podocytopathy, Nephrology, vol.24, issue.12, pp.1241-1247, 2019.

G. Fernandez-fresnedo, A. Segarra, E. González, S. Alexandru, R. Delgado et al., Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis, Clinical Journal of the American Society of Nephrology, vol.4, issue.8, pp.1317-1323, 2009.

W. Y. Kong, R. Swaminathan, and A. Irish, Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature, International Urology and Nephrology, vol.45, issue.3, pp.795-802, 2012.

J. Guitard, A. Hebral, F. Fakhouri, D. Joly, E. Daugas et al., Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance, Nephrology Dialysis Transplantation, vol.29, issue.11, pp.2084-2091, 2014.

C. King, S. Logan, S. W. Smith, and P. Hewins, The efficacy of rituximab in adult frequently relapsing minimal change disease, Clinical Kidney Journal, vol.10, issue.1, p.sfw100, 2016.

I. Dasilva, A. Huerta, L. Quintana, B. Redondo, E. Iglesias et al., Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain, BioDrugs, vol.31, issue.3, pp.239-249, 2017.

R. Fenoglio, S. Sciascia, G. Beltrame, P. Mesiano, M. Ferro et al., Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome, Oncotarget, vol.9, issue.48, pp.28799-28804, 2018.

T. Katsuno, T. Masuda, S. Saito, N. Kato, T. Ishimoto et al., Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study, Clinical and Experimental Nephrology, vol.23, issue.2, pp.207-214, 2018.

Y. Iwabuchi, Y. Miyabe, S. Makabe, M. Nakano, S. Manabe et al., Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease, Medicine, vol.97, issue.42, p.e12704, 2018.

H. François, E. Daugas, A. Bensman, and P. Ronco, Unexpected Efficacy of Rituximab in Multirelapsing Minimal Change Nephrotic Syndrome in the Adult: First Case Report and Pathophysiological Considerations, American Journal of Kidney Diseases, vol.49, issue.1, pp.158-161, 2007.

J. M. Hofstra, J. K. Deegens, and J. F. Wetzels, Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?, Nephrology Dialysis Transplantation, vol.22, issue.7, pp.2100-2102, 2007.

T. Yang, C. C. Nast, A. Vo, and S. C. Jordan, Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy, Nephrology Dialysis Transplantation, vol.23, issue.1, pp.377-380, 2007.

Y. Sawara, M. Itabashi, C. Kojima, H. Tabata, D. Kamei et al., Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome, Clinical Nephrology, vol.72, issue.07, pp.69-72, 2009.

N. Kurosu, H. Sugiura, C. Iwasaki, Y. Asamiya, C. Kojima et al., Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome, Internal Medicine, vol.48, issue.21, pp.1901-1904, 2009.

A. Beco, I. Castro-ferreira, L. Coentrao, R. Neto, S. Sampaio et al., Rituximab for steroid-dependent nephrotic syndrome, Clin Nephrol, vol.74, issue.4, pp.308-310, 2010.

A. Ochi, T. Takei, K. Nakayama, C. Iwasaki, D. Kamei et al., Rituximab Treatment for Adult Patients with Focal Segmental Glomerulosclerosis, Internal Medicine, vol.51, issue.7, pp.759-762, 2012.

N. Amemiya, T. Takei, C. Kojima, H. Nokiba, M. Itabashi et al., Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome, Clinical and Experimental Nephrology, vol.15, issue.6, pp.933-936, 2011.

A. Kronbichler, P. König, M. Busch, G. Wolf, G. Mayer et al., Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases, Wiener klinische Wochenschrift, vol.125, issue.11-12, pp.328-333, 2013.

M. Marasa, P. Cravedi, B. Ruggiero, and P. Ruggenenti, Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab, Case Reports, vol.2014, issue.aug24 1, pp.bcr2014205507-bcr2014205507, 2014.

I. M. Rood, J. Huussen, J. F. Wetzels, and J. K. Deegens, Rituximab can induce remission of nephrotic syndrome in the absence of peripheral B-cells, Nephrology, vol.20, issue.9, pp.667-668, 2015.

R. Ramachandran, V. Rajakumar, R. Duseja, V. Sakhuja, and V. Jha, Successful treatment of adult-onset collapsing focal segmental glomerulosclerosis with rituximab, Clinical Kidney Journal, vol.6, issue.5, pp.500-502, 2013.

W. Leng, G. Mustafar, R. Kamaruzaman, and L. , Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis, Acta Med Indones, vol.50, issue.3, pp.237-243, 2018.

M. Yamazaki, H. Sugiura, Y. Iwatani, M. Kyoda, H. Nokiba et al., Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome, Case Reports in Nephrology, vol.2019, pp.1-4, 2019.

. Serment-d'hippocrate, HIPPOCRATE LA NATURE DE L'HOMME/ ??????????? ???? ?????? ????????, Hippocrate La nature de l'homme

J. Wittmann, « C?est poète que je veux être ! C?est poète que je suis ! ». La place paradoxale de la poésie dans la carrière littéraire de Gide, La poésie, entre vers et prose, pp.139-149

, 3.1.1. Emploi dans le secteur de la santé et des services sociaux en pourcentage de l'emploi civil total, 1995 et 2009 (ou année la plus proche)

. Prâevost, Â. M. Chomprâe, A. Deleyre, J. Green, A. Meusnier-de-querlon et al., Histoire gâenâerale des voyages, ou, Nouvelle collection de toutes les relations de voyages par mer et par terre, qui ont âetâe publiâees jusqu'áa present dans les diffâerentes langues de toutes les nations connues : contenant ce qu'il y a de plus remarquable, de plus utile et de mieux averâe dans les pays ou les voyageurs ont penetrâe : touchant leur situation, leur âetendue, leurs limites, leurs divisions, leur climat, leur terroir, leurs productions, leurs lacs, leurs rivieres, leurs montagnes, leurs mines, leurs citâes & leurs principales villes, leurs ports, leurs rades, leurs edifices, &c. : avec les moeurs et les usages des habitans, leur religion, leur gouvernement, leurs arts et leurs sciences, leur commerce et leurs manufactures : pour former un systâeme complet d'histoire et de gâeographie moderne, qui representera l'âetat actuel de toutes les nations : enrichi de cartes gâeographiques nouvellement composâees sur les observations les plus autentiques :, 1746.

. Prâevost, Â. M. Chomprâe, A. Deleyre, J. Green, A. Meusnier-de-querlon et al., Histoire gâenâerale des voyages, ou, Nouvelle collection de toutes les relations de voyages par mer et par terre, qui ont âetâe publiâees jusqu'áa present dans les diffâerentes langues de toutes les nations connues : contenant ce qu'il y a de plus remarquable, de plus utile et de mieux averâe dans les pays ou les voyageurs ont penetrâe : touchant leur situation, leur âetendue, leurs limites, leurs divisions, leur climat, leur terroir, leurs productions, leurs lacs, leurs rivieres, leurs montagnes, leurs mines, leurs citâes & leurs principales villes, leurs ports, leurs rades, leurs edifices, &c. : avec les moeurs et les usages des habitans, leur religion, leur gouvernement, leurs arts et leurs sciences, leur commerce et leurs manufactures : pour former un systâeme complet d'histoire et de gâeographie moderne, qui representera l'âetat actuel de toutes les nations : enrichi de cartes gâeographiques nouvellement composâees sur les observations les plus autentiques :, 1746.

M. Sandras, « Je ne suis pas un écrivain, je suis le poète qui chante » Les entretiens de Paul Fort avec Michel Manoll, Écrivains au micro, pp.201-15

M. Sandras, « Je ne suis pas un écrivain, je suis le poète qui chante » Les entretiens de Paul Fort avec Michel Manoll, Écrivains au micro, pp.201-15

A. Niess, Conclusion. Le spectre des deux-cents familles ?, L?hérédité en République, pp.327-328, 2012.

, Si je constate une violation de mes droits de propriété intellectuelle, que dois-je ou que puis-je faire?, 2004.